years, genome-wide association studies have found new evidence for SZ and BD genetic basis and shown that single-nucleotide polymorphisms (SNPs) affect the function of certain receptors and corresponding neurotransmitters and contribute to SZ and BD development. [4] [5] [6] [7] The µ-opioid receptor (MOR) encoded by µ-opioid receptor gene (OPRM1) is widely distributed in the central nervous system, [6, 8, 9] and its expression is very prominent in caudate, putamen, thalamus, and globus pallidus. [6, 10] The MOR has a high affinity for opioid drugs such as methadone, morphine, and heroin. The symptoms related to opiate drug withdrawal, euphoria and analgesia are believed to be caused by MORs. [6, 11, 12] A number of studies have reported more than 250 SNPs in the OPRM1 gene. [6, [13] [14] [15] A single-nucleotide polymorphism (A118G, rs1799971) in the OPRM1 gene results in replacement of asparagine (Asn) with aspartic acid (Asp) at amino acid position 40 which leads to a change at N-glycosylation site and decreased expression of the receptor. [6, 8, 12] Studies on the association between this SNP and SZ/BD disorders have provided contradicting results. [6, 12, 16, 17] The different literature findings for the A118G genotype report the distribution of alleles and genotypes. The genotypic and allelic frequencies are similar among different populations. The variant genotypes for A118G, AG and GG, are reported in 10.5% to 18.8% of the population (NCBI-rs1799971).
Since there is a body of conflicting and controversial evidence regarding the basic role of opioid receptors and their SNPs in psychotic disorders, this case-control study was designed to investigate the relationship between OPRM1 SNP (rs1799971, A118G) and SZ/BD patients in the Iranian population.
MATERIALS AND METHODS
The sample size of this case-control study consisted of 134 patients with SZ (94 females and 40 males; mean age: 38.01 ± 10.57 years old) and 69 patients with BD (39 females and 30 males; mean age: 37.84 ± 11.92 years old) and 389 healthy controls (HCs) (215 females and 174 males; mean age: 41.67 ± 22.06 years old). All the patients were hospitalized at one of the psychiatry hospitals of Iran University and Mehrvarzan-e-Saba Gostar Medical, Rehabilitation and Maintenance Centre of chronic mental patients, Karaj. Two certified psychiatrists made the consensus diagnosis with regard to the diagnostic and manual of Mental Disorder-Forth edition IV diagnostic criteria. Individuals with a history of severe medical diseases such as neurological disorders, diabetes, hypertension, cardiovascular diseases, and substance dependence were excluded from this study. The HC volunteers participated in this study were from Tehran University of Medical Sciences. The HCs were first interviewed using a neuropsychiatric approach and then by a psychiatrist. All individuals with a history of SZ, BD, or addiction were excluded from the HCs.
Informed consent forms were signed by all the participants for joining the study. The control and patient groups were matched for gender and age.
DNA analysis
DNA was extracted from peripheral blood mononuclear cells using the High Pure Viral Nucleic Acid Kit (Roche, Germany) according to the manufacturer's instructions. A commercial kit from Thermo Fisher Scientific (4351379) was used to detect the OPRM1 polymorphism (rs1799971). The assay takes advantage of specific primers to amplify OPRM1 gene and 2 probes to specifically detect the two SNPs. A VIC-labeled probe detects the A/A allele and the FAM-labeled probe detects A/G allele. The TaqMan real-time PCR was performed using automated ABI one plus system (Applied Biosystems, Foster City, CA). The reaction mixture of a total volume of 20 µl was comprised of 10 µl of TaqMan universal PCR master mix (Applied Biosystems, Foster City, CA), 5 µl of the extracted DNA, 4.8 µl of distilled water, and 0.2 µl of primers and probes mix. The condition for real-time PCR SNP detection consisted of an initial denaturation phase at 95°C for 10 min followed by 50 cycles at 95°C for 15 s and annealing/extension at 60°C for 90 s.
Statistical analysis
The real-time PCR data obtained from the patients and HCs were compared for genotype and allele frequencies using SPSS version 22 software. Using Chi-square distribution of a 2 × 2 table, genotype distribution and allele frequency variation between patients and HCs, and the deviation from Hardy-Weinberg equilibrium was surveyed for SNP analysis.
RESULTS
The OPRM1 A118G SNP (rs1799971) was tested in 203 SZ and BD patients together with 389 HCs. No significant deviation from the Hardy-Weinberg equilibrium was observed in either of the patient groups or the HCs for this SNP. The OPRM1 SNP analyses based on gender and in case and control groups are shown in Table 1 , and the results of genotyping of the OPRM1 gene polymorphism are demonstrated in Table 2 . The total of 152 patients had AA genotype, 46 patients carried AG genotype, and five patients were GG homozygotes. In the HCs, 276 individuals carried the AA genotype, 97 individuals were AG heterozygotes and 16 individuals were GG homozygotes.
Comparison of genotype frequencies showed no significant difference between the studied groups (P = 0.451). No significant difference was also found when the allelic frequencies between the two groups were compared, suggesting that the distribution of the OPRM1 A118G SNP is similar between the healthy individuals and BD/SZ patients. Taken together, our results did not support the previous studies reporting the contribution of this specific SNP in BD/SZ development. addiction to smoking in comparison with those with the AA homozygote. [21] In a case-control study of 183 suicide cases and 374 HCs, it was shown that the A118G polymorphism was significantly different among the two groups suggesting the possible association between suicide and A118G. [22] The present study was performed for detection of the A118G SNP in the OPRM1 gene of SZ and BD patients.
A number of studies have reported an association between the rs1799971 polymorphism in the OPRM1 gene and the increased risk of SZ in the males. [12] It was also shown that the occurrence of the G allele was significantly lower in tardive dyskinesia patients. [16] Another study confirmed the previous results by showing a less frequent G allele in participants with tardive dyskinesia among SZ patients. [17] A study by Volk et al. depicted that the level of MOR mRNA in SZ patients was increased. [23] Moreover, they showed that the G allele of rs1799971 can affect MOR function, resulting in decreased expression of this receptor. [16, 17, 24] A recent study of OPRM1 polymorphism with SZ suggested that G allele of rs1799971 has decreased risk in these patients. [6] Surprisingly, in our analysis, we did not find any association between OPRM1 rs1799971 SNP and the SZ and BD disorders. The incidence of complex disorders such as SZ is highly multifactorial which means no single gene may account for these disorders and multiple factors can play roles in their occurrences. [12, 16, 17] Meanwhile, there are several possibilities for the contrast between our findings and previous studies. As requested we can write conclusions and from this part can move under the conclusion heading.
CONCLUSION
The lack of association between the studied SNP and BD and SZ disorders in this study can be the result of population characteristics, geographic location, and clinical heterogeneity. For adding more precious insights into the implications of the OPRM1 gene polymorphism and BD/SZ disorder association, further investigations using a larger sample size and family-based surveys are suggested.
DISCUSSION
The MOR encoded by OPRM1 is widely distributed in the brain with different roles in diverse areas such as social status, stress, memory, drinking, eating, sexual activity, mental illness, mood, seizures, and neurologic disorders. [18] MORs are believed to regulate many opioidergic actions such as analgesia, euphoria, and opiate drug withdrawal. [11] There are high-affinity interactions between this receptor and the exogenous opioid drugs such as methadone, morphine, and heroin. The MOR controls the proliferation of oligodendrocyte progenitors and thickness of myelin sheaths and the volume of brain white matter. In SZ patients, there is an impairment of the myelination in the cortex. [12, 19] Genetic association studies have shown that certain SNPs in OPRM1 may contribute to disease pathogenesis by affecting the oligodendrocytes density and myelination rate. [12, 19] Among all SNPs, rs1799971 in coding region with a minor allele frequency of 20%, the 118A>G SNP (Asn40Asp) is the most important studied SNP of the OPRM1 gene. [8] This polymorphism has been analyzed in different studies, for instance in one research by Hirasawa-Fujita et al., A118G and dopamine D2 receptor (DRD2) Taq1A (rs1800497) polymorphisms, smoking habits and sex differences among patients with SZ or BD were analyzed. The results showed that A118G increases smoking in patients with SZ and alteration of DRD2 receptor function also increases smoking in females with SC but not BD. [20] The results of study by Wang et al. showed that Caucasians carrying the G allele of the A118G were susceptible for 
